| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 790 | 531 | 235 | 685 |
| Depreciation and amortization | 425 | 283 | 140 | 358 |
| Provision for credit losses | 2 | 2 | 1 | 4 |
| Deferred income tax expense (benefit) | 118 | 8 | 7 | -21 |
| Stock-based compensation expense | 63 | 43 | 22 | 61 |
| Other, net | -37 | -26 | 1 | -17 |
| Accounts receivable | 153 | 115 | 101 | 140 |
| Accounts payable and accrued expenses | 113 | -11 | -53 | -102 |
| Income taxes payable | -1 | 9 | 15 | 31 |
| Other assets and liabilities, net | -27 | -82 | -49 | 23 |
| Net cash provided by operating activities | 1,421 | 858 | 314 | 870 |
| Business acquisitions, net of cash acquired | 51 | 17 | 0 | 1,781 |
| Capital expenditures | 369 | 225 | 117 | 302 |
| Other investing activities, net | 20 | -3 | -2 | -37 |
| Net cash used in investing activities | -440 | -239 | -115 | -2,046 |
| Proceeds from borrowings | 410 | 400 | 215 | 1,846 |
| Repayments of debt | 1,011 | 1,001 | 600 | 302 |
| Purchases of treasury stock | 150 | - | - | - |
| Exercise of stock options | 61 | 42 | 29 | 52 |
| Employee payroll tax withholdings on stock issued under stock-based compensation plans | 44 | 42 | 42 | 24 |
| Dividends paid | 263 | 174 | 84 | 247 |
| Distributions to noncontrolling interest partners | 43 | 29 | 18 | 35 |
| Other financing activities, net | -61 | -50 | -61 | -36 |
| Net cash (used in) provided by financing activities | -1,101 | -854 | -561 | 1,254 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 3 | 5 | 1 | - |
| Net change in cash and cash equivalents and restricted cash | -117 | -230 | -361 | 78 |
| Cash and cash equivalents at beginning of period | 549 | 549 | 549 | 686 |
| Cash and cash equivalents at end of period | 432 | 319 | 188 | 764 |
QUEST DIAGNOSTICS INC (DGX)
QUEST DIAGNOSTICS INC (DGX)